MIRA PHARMACEUTICALS, INC. Logo

MIRA PHARMACEUTICALS, INC.

Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.

MIRA | US

Overview

Corporate Details

ISIN(s):
US60458C1045
LEI:
Country:
United States of America
Address:
1200 BRICKELL AVENUE, 33131 MIAMI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MIRA Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic and neuropsychiatric disorders. The company's pipeline is centered on two primary neuroscience programs. One program is developing Ketamir-2, a next-generation oral ketamine analog. The other is focused on a new molecular synthetic analog of THC (tetrahydrocannabinol). MIRA aims to address unmet medical needs by creating advanced, patent-protected treatment options for a range of central nervous system conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all MIRA PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MIRA PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MIRA PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Pacira BioSciences, Inc. Logo
Advancing non-opioid therapies for postsurgical, chronic, and musculoskeletal pain.
United States of America PCRX
PAINREFORM LTD. Logo
Specialty pharma developing extended-release drugs for post-operative pain management.
United States of America PRFX
PAION AG Logo
Developed drugs for hospital-based sedation, anesthesia, and critical care.
Germany PA8
PALISADE BIO, INC. Logo
Developing oral precision therapies for inflammatory and fibrotic intestinal diseases like colitis.
United States of America PALI
PALVELLA THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing topical therapies for rare genetic skin diseases.
United States of America PVLA
Pangen Biotech Inc. Logo
Develops biosimilars and provides CHO-based CDMO services for the global biopharma industry.
South Korea 222110
Pasithea Therapeutics Corp. Logo
Developing innovative therapeutics for CNS disorders (ALS, MS) and RASopathies.
United States of America KTTA
Pelthos Therapeutics Inc. Logo
Biopharma with an approved gel for molluscum, advancing a nitric oxide-based pipeline.
United States of America PTHS
Pentixapharm Holding AG Logo
Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.
Germany PTP
PeopleBio, Inc. Logo
Develops blood tests for early diagnosis of neurodegenerative diseases like Alzheimer's.
South Korea 304840

Talk to a Data Expert

Have a question? We'll get back to you promptly.